Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.TorreyPines Therapeutics, a US biopharmaceutical company, said it has extended its exclusive collaboration agreement with Eisai Company that focuses on the discovery of molecules to treat Alzheimer's disease.
Subscribe to our email newsletter
TorreyPines said under the agreement, which began in February 2005, Eisai has exclusive rights of first negotiation and refusal for validated compounds that are discovered through the research. TorreyPines and Eisai may enter into development agreements involving the validated compounds.
“We are excited about extending this agreement with Eisai, a leader in Alzheimer's disease research and treatment,” said Neil Kurtz, managing director, president and CEO of TorreyPines.
“We look forward to advancing the small molecule program further with Eisai's support, as well as to continuing to work with them on our initial research collaboration to identify genetically-validated pharmaceutical targets for Alzheimer's disease,” Mr Kurtz added.